Medically reviewed by Biljana Srbinovska, MPharm. Last reviewed July 2026.
Fewer medications are FDA-approved for childhood anxiety than most parents assume. Only two are approved for generalised anxiety disorder in children, duloxetine and escitalopram, both from age seven. Several more are approved for OCD. For social anxiety, separation anxiety, and panic disorder, nothing is approved in under-18s, so those are treated off-label. And the strongest evidence in this field says something worth knowing before any prescription: therapy combined with medication outperforms either one alone by a wide margin.
What Is Actually FDA-Approved
| Medication | Approved for | Minimum age |
|---|---|---|
| Duloxetine (Cymbalta) | Generalised anxiety disorder | 7 |
| Escitalopram (Lexapro) | Generalised anxiety disorder | 7 |
| Sertraline (Zoloft) | OCD | 6 |
| Fluoxetine (Prozac) | OCD | 7 |
| Fluvoxamine | OCD | 8 |
| Clomipramine (Anafranil) | OCD | 10 |
Escitalopram’s approval for paediatric GAD came in 2023, which is recent enough that older articles frequently miss it.
A Common Point of Confusion
Some medications are approved for depression in children but not for anxiety. Fluoxetine is approved for paediatric depression from age 8, and escitalopram from age 12. Fluoxetine’s OCD approval does not extend to generalised anxiety, social anxiety, separation anxiety, or panic disorder.
This matters when reading drug information, because “approved for children” is not the same as “approved for your child’s condition.”
Why Most Prescriptions Are Off-Label
No medication is FDA-approved in under-18s for social anxiety disorder, separation anxiety disorder, panic disorder, or specific phobia. These are among the most common anxiety presentations in children, and they are routinely treated off-label, usually with SSRIs such as sertraline, fluoxetine, or escitalopram.
Off-label prescribing is legal, extremely common in paediatrics, and supported by evidence. It reflects the economics of running trials in children more than any doubt about whether the drugs work. That said, a prescriber should tell you when a medication is being used off-label and why. If that has not been explained, ask.
The Boxed Warning, Accurately
Every antidepressant carries an FDA boxed warning about an increased risk of suicidal thoughts and behaviours in children, adolescents, and young adults up to age 24, particularly during the first months of treatment and after any dose change.
The numbers behind it are worth understanding rather than just fearing. In the FDA’s pooled analysis of 24 paediatric trials involving roughly 4,400 patients, suicidal thinking or behaviour occurred in about 4% of those on medication versus 2% on placebo, meaning roughly two additional cases per hundred. No completed suicides occurred in those trials. The warning concerns thoughts and behaviours, not deaths.
The other half of the picture matters too: untreated anxiety and depression carry their own substantial risks, including suicide risk. The warning is a reason for close monitoring, not a reason to leave a child untreated.
What monitoring looks like in practice: frequent contact in the early weeks, at every dose change, and ongoing follow-up with the prescriber. Watch for worsening anxiety, agitation, irritability, trouble sleeping, impulsivity, or any new talk of self-harm.
What the Evidence Says About Therapy vs Medication
This is the most useful thing on this page. The Child/Adolescent Anxiety Multimodal Study followed 488 children aged 7 to 17 with generalised anxiety, separation anxiety, or social phobia. After 12 weeks, response rates were:
| Treatment | Response rate |
|---|---|
| CBT plus sertraline | 80.7% |
| CBT alone | 59.7% |
| Sertraline alone | 54.9% |
| Placebo | 23.7% |
More than 80% of responders maintained their gains at 24 and 36 weeks. The American Academy of Child and Adolescent Psychiatry’s 2020 guideline supports both cognitive behavioural therapy and SSRIs as first-line treatment, with psychotherapy alone generally preferred for mild anxiety and medication added for moderate to severe symptoms or when other conditions are present.
The practical implication: if a child is starting medication without any therapy alongside it, that is worth raising with the prescriber. Combination treatment is not a fringe preference, it is what the largest trial in this area found.
Why Benzodiazepines Are Not Used
Medications such as alprazolam or lorazepam are not recommended for treating anxiety in children. Evidence reviews have found insufficient evidence that they work for paediatric anxiety, and the concerns are significant: sedation, effects on concentration and school performance, paradoxical agitation in some children, tolerance, dependence, and difficult withdrawal.
They are occasionally used briefly for a specific acute situation, but they are not a maintenance treatment for childhood anxiety.
What Parents Should Expect
Timeline. Meaningful improvement usually takes four to six weeks, and full response can take eight to twelve. Side effects often appear before benefits do, which is the point at which families most often give up. Knowing this in advance helps.
Do not stop abruptly. Stopping an SSRI suddenly commonly causes discontinuation symptoms. Any taper should be planned with the prescriber, including if you decide the medication is not working.
Contact the prescriber urgently for new or worsening talk of suicide or self-harm, severe agitation or restlessness, a marked change in behaviour or unusually elevated mood, or symptoms such as high fever with confusion, muscle rigidity, and tremor.
If your child is in immediate danger, call 911. For a mental health crisis, the 988 Suicide and Crisis Lifeline is available 24 hours a day by call or text.
Paediatric Anxiety Medication FAQs
Which anxiety medications are FDA-approved for children?
For generalised anxiety disorder, duloxetine and escitalopram, both from age 7. For OCD, sertraline from age 6, fluoxetine from 7, fluvoxamine from 8, and clomipramine from 10.
No. Nothing is FDA-approved in under-18s for social anxiety disorder, separation anxiety disorder, panic disorder, or specific phobia. These are treated off-label, usually with SSRIs.
Is off-label prescribing safe?
Off-label use is legal, common in paediatrics, and evidence-supported. It reflects gaps in paediatric trials rather than a lack of evidence that the drugs help. Your prescriber should tell you when a medication is off-label and explain why.
What does the boxed warning actually say?
That antidepressants increase the risk of suicidal thoughts and behaviours in people under 25, especially early in treatment and after dose changes. In pooled paediatric trials the rate was about 4% on medication versus 2% on placebo, with no completed suicides. It calls for close monitoring rather than avoiding treatment.
Is therapy or medication better for childhood anxiety?
Combination works best. In the CAMS trial, CBT plus sertraline produced an 80.7% response rate, against 59.7% for CBT alone and 54.9% for medication alone. Guidelines favour therapy alone for mild anxiety and adding medication for moderate to severe cases.
How long before the medication works?
Usually four to six weeks for meaningful improvement and up to eight to twelve weeks for full effect. Side effects often show up first, so early discouragement is common and worth discussing with the prescriber rather than stopping.
